Search Results - "Sherrill, B.H."

Corrections to “Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer” by Wu, Y., Amonkar, M.M., Sherrill, B.H., O'Shaughnessy, J., Ellis, C., Baselga, J., Blackwell, K.L., Burstein, H.J.

Get full text

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer by Wu, Y., Amonkar, M.M., Sherrill, B.H., O’Shaughnessy, J., Ellis, C., Baselga, J., Blackwell, K.L., Burstein, H.J.

“…Progression-free survival (PFS) was significantly longer for the lapatinib plus trastuzumab (L+T) arm than for L alone in a phase III, randomized, open-label…”
Get full text

PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: baseline health and healthcare utilization of the US sample by Wolf, A.M, Finer, N, Allshouse, A.A, Pendergast, K.B, Sherrill, B.H, Caterson, I, Hill, J.O, Aronne, L.J, Hauner, H, Radigue, C, Amand, C, Despres, J.-P

“…To summarize baseline characteristics, health conditions, resource utilization and resource cost for the US population for the 90-day period preceding…”
Get full text